Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO

The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

Read more

Corporate Sponsor Program

EHA Ranking for 2024 is now accessible via this link. "Alone we can do so little; together we can do so much.

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

ASCAT2024

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 19th Annual Sickle Cell & Thalassaemia Conference.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!

 

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia 

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…

Read more

ASCAT 2023

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 18th Annual Sickle Cell & Thalassaemia Conference.

Read more